Literature DB >> 23414584

IGF-1R inhibition: right direction, wrong pathway?

Sheridan Wilson1, Stephen K Chia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23414584     DOI： 10.1016/S1470-2045(13)70019-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

Authors:  Marta Schirripa; Wu Zhang; Volker Heinemann; Shu Cao; Satoshi Okazaki; Dongyun Yang; Fotios Loupakis; Martin D Berger; Yan Ning; Yuji Miyamoto; Mitsukuni Suenaga; Roel F Gopez; Jordan D West; Diana Hanna; Afsaneh Barzi; Alfredo Falcone; Sebastian Stintzing; Heinz-Josef Lenz
Journal:  Int J Cancer       Date:  2017-05-10       Impact factor: 7.396

Review 2.  Could Intermittent Energy Restriction and Intermittent Fasting Reduce Rates of Cancer in Obese, Overweight, and Normal-Weight Subjects? A Summary of Evidence.

Authors:  Michelle N Harvie; Tony Howell
Journal:  Adv Nutr       Date:  2016-07-15       Impact factor: 8.701

3.  Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer.

Authors:  Michelle Harvie; Mary Pegington; Sacha J Howell; Nigel Bundred; Phil Foden; Judith Adams; Lee Graves; Alastair Greystoke; Mark P Mattson; Roy G Cutler; Julie Williamson; Karen Livingstone; Debbie McMullen; Katharine Sellers; Cheryl Lombardelli; Grace Cooper; Sarah McDiarmid; Anthony Howell
Journal:  Br J Cancer       Date:  2021-12-15       Impact factor: 9.075

Review 4.  Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.

Authors:  Aaron Simpson; Wilfride Petnga; Valentine M Macaulay; Ulrike Weyer-Czernilofsky; Thomas Bogenrieder
Journal:  Target Oncol       Date:  2017-10       Impact factor: 4.493

Review 5.  Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy.

Authors:  Xiao Qu; Zhinan Wu; Wei Dong; Tiehong Zhang; Liguang Wang; Zhaofei Pang; Wei Ma; Jiajun Du
Journal:  Oncotarget       Date:  2017-04-25

6.  Integrated bioinformatics analysis to decipher molecular mechanism of compound Kushen injection for esophageal cancer by combining WGCNA with network pharmacology.

Authors:  Wei Zhou; Jiarui Wu; Jingyuan Zhang; Xinkui Liu; Siyu Guo; ShanShan Jia; Xiaomeng Zhang; Yingli Zhu; Miaomiao Wang
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.